FDA Approves mFLUSIVA, Moderna’s First mRNA-Based Flu Vaccine
The FDA approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine authorized in the United States, for adults age 50 and older. The approval is split into two tiers: full approval for adults…
